Madison Asset Management LLC Takes Position in Regeneron Pharmaceuticals, Inc. $REGN

Madison Asset Management LLC purchased a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 5,729 shares of the biopharmaceutical company’s stock, valued at approximately $3,572,000.

A number of other large investors have also added to or reduced their stakes in REGN. Orbimed Advisors LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter worth about $11,358,000. Lockheed Martin Investment Management Co. bought a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter valued at about $2,702,000. BlackRock Inc. purchased a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at about $5,682,636,000. National Pension Service increased its position in shares of Regeneron Pharmaceuticals by 29.8% during the fourth quarter. National Pension Service now owns 360,988 shares of the biopharmaceutical company’s stock valued at $278,636,000 after buying an additional 82,853 shares during the period. Finally, Eurizon Capital SGR S.p.A. bought a new position in Regeneron Pharmaceuticals in the fourth quarter worth about $10,472,000. Institutional investors own 83.31% of the company’s stock.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, Director Kathryn Guarini sold 400 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $320,000.00. Following the sale, the director owned 603 shares in the company, valued at $482,400. This trade represents a 39.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 800 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $640,000.00. Following the sale, the director owned 1,703 shares of the company’s stock, valued at approximately $1,362,400. This trade represents a 31.96% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 1,400 shares of company stock valued at $1,090,030. Insiders own 6.97% of the company’s stock.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: The FDA approved Pasatru (garetosmab-grts) for adults with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder that causes abnormal bone formation. Approval was supported by Phase 3 OPTIMA data showing a 90% or greater reduction in new heterotopic-ossification lesions at 56 weeks, along with fewer clinician-assessed flare-ups. Pasatru is described as the first and only FDA-approved treatment demonstrating these benefits, adding a specialized rare-disease product to Regeneron’s commercial portfolio. Reuters FDA approval article
• Positive Sentiment: The approval creates a potential new revenue stream and strengthens Regeneron’s focus on high-complexity immunology and rare diseases. However, FOP’s very small patient population limits the drug’s absolute market opportunity, while competition from Ipsen could affect adoption and sales. BioPharma Dive Pasatru article
• Neutral Sentiment: Regeneron also reported an update to its Phase 2 study of olatorepatide, signaling continued efforts to enter the obesity-treatment market. The trial remains mid-stage, so any commercial benefit is still several steps away and dependent on future efficacy and safety results. TipRanks olatorepatide article
• Neutral Sentiment: Leerink Partners raised its price target to $824, indicating limited near-term upside relative to the trading level and suggesting the FDA approval may already be substantially reflected in the valuation. Leerink Partners price-target article
• Negative Sentiment: Multiple law firms publicized a securities class action and a September 14, 2026 lead-plaintiff deadline. The claims relate to disclosures surrounding the Phase 3 Fianlimab-Libtayo melanoma trial, including a protocol amendment and concerns that previously positive messaging did not adequately reflect statistical and trial risks. The notices are largely duplicative, but they reinforce legal, reputational and pipeline uncertainty for REGN. Regeneron securities class-action notice

Wall Street Analyst Weigh In

REGN has been the subject of several research analyst reports. Weiss Ratings restated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a report on Wednesday, June 24th. Sanford C. Bernstein raised Regeneron Pharmaceuticals to a “hold” rating in a research report on Wednesday, July 29th. Truist Financial raised their target price on Regeneron Pharmaceuticals from $769.00 to $772.00 and gave the company a “buy” rating in a research note on Friday, July 31st. Benchmark upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 target price for the company in a research note on Tuesday, July 7th. Finally, Canaccord Genuity Group dropped their price target on Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating on the stock in a research report on Tuesday, May 19th. Sixteen investment analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $801.70.

Regeneron Pharmaceuticals Trading Down 1.7%

Shares of REGN opened at $826.64 on Friday. The company’s fifty day simple moving average is $692.65 and its 200-day simple moving average is $715.90. The company has a market cap of $85.11 billion, a P/E ratio of 20.43, a P/E/G ratio of 1.43 and a beta of 0.22. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals, Inc. has a twelve month low of $541.00 and a twelve month high of $844.92.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, topping analysts’ consensus estimates of $10.16 by $4.13. The company had revenue of $4.29 billion for the quarter, compared to analyst estimates of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The firm’s revenue for the quarter was up 16.7% on a year-over-year basis. During the same period in the prior year, the company posted $12.81 EPS. As a group, analysts expect that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, August 31st. Investors of record on Tuesday, August 18th will be paid a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date of this dividend is Tuesday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 9.29%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.